An Open-label Multi-cohort Dose-escalation Study to Evaluate the Tolerance, Safety, and Pharmacokinetics of GNR-055 (GENERIUM JSC, Russia) in Healthy Volunteers With a Single Intravenous Administration
Latest Information Update: 16 Oct 2020
Price :
$35 *
At a glance
- Drugs GNR 055 (Primary)
- Indications Lysosomal storage diseases
- Focus Adverse reactions
- Sponsors GENERIUM Pharmaceuticals
- 13 Oct 2020 Status changed from recruiting to completed.
- 02 Jan 2020 New trial record